Mirum Pharmaceuticals, Inc. (MIRM) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$23M, a net margin of -4.5%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $671M and net income -$904M.
Free cash flow was $55M in fiscal 2025 and positive in 2 of the 7 years shown.
The diluted share count rose 337% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $671M | $521M | $337M | $186M | $77M | $19M | $0 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$896M | -$22M | -$88M | -$109M | -$131M | -$173M | -$104M | -$55M |
| Net income | -$904M | -$23M | -$88M | -$163M | -$136M | -$84M | -$103M | -$53M |
| EPS (diluted) | $-14.47 | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 | $-4.09 | $-4.58 |
| R&D | $352M | $186M | $141M | $103M | $107M | $131M | $82M | $43M |
| Revenue growth | — | +54.7% | +80.8% | +141.9% | +302.7% | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$271M | $56M | $10M | -$71M | -$120M | -$133M | -$89M | -$39M |
| Capital spending | -$3M | -$954000 | -$993000 | -$109000 | -$278000 | -$24000 | -$225000 | -$281000 |
| Free cash flow | -$274M | $55M | $9M | -$71M | -$120M | -$133M | -$89M | -$40M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $119M | $71M | $48M | $35M | $27M | $23M | $13M | $6M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $383M | $280M | $286M | $152M | $157M | $232M | $117M |
| Debt | — | $10M | $10M | $2M | $2M | $3M | $3M | $4M |
| Equity | — | $315M | $226M | $249M | $142M | $120M | $172M | $130M |
| Total assets | — | $843M | $671M | $647M | $353M | $295M | $241M | $147M |
| Shares (diluted) | 66M | 50M | 48M | 41M | 34M | 30M | 25M | 11M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -133.6% | -4.2% | -26.0% | -58.6% | -170.3% | -906.1% | — | — |
| Net margin | -134.8% | -4.5% | -26.1% | -87.7% | -176.0% | -438.8% | — | — |
| FCF margin | -40.8% | 10.5% | 2.8% | -38.1% | -156.3% | -693.8% | — | — |
| ROIC | — | -5.4% | -29.4% | -34.4% | -86.9% | -111.5% | -47.0% | -32.3% |
| ROE | — | -7.4% | -39.0% | -65.7% | -95.5% | -69.9% | -60.0% | -40.3% |
Frequently asked questions
What is Mirum Pharmaceuticals’s annual revenue?
$521M in fiscal 2025 and $671M over the twelve months to September 30, 2026.
How much profit does Mirum Pharmaceuticals make?
Net income was -$23M in fiscal 2025 (net margin -4.5%).
Is Mirum Pharmaceuticals’s revenue growing?
Yes: revenue rose 54.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.